A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with
Y. Hettema, W. Huisman, D. de Vos, E. Wunderink, D. S. Voncken (Haarlem, Nijmegen, The Netherlands)
Source: Annual Congress 2001 - Inhalation devices and technique
Session: Inhalation devices and technique
Session type: Thematic Poster Session
Number: 543
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Hettema, W. Huisman, D. de Vos, E. Wunderink, D. S. Voncken (Haarlem, Nijmegen, The Netherlands). A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with. Eur Respir J 2001; 16: Suppl. 31, 543
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017
A double-blind, single dose, four period, crossover study to demonstrate the equivalence between the two HFA formulations of formoterol fumarate; using serial spirometry measurements for 12 hrs Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
A multi-centre, randomised, cross-over study to investigate therapy adherence with and preference for inhaled maintenance therapy via separate Diskus versus a combination product in one Diskus Source: Eur Respir J 2002; 20: Suppl. 38, 448s Year: 2002
Randomized, double blind, double dummy, placebo-controlled trial designed for comparing the effectiveness of formoterol (Foradil®) Aerolizer® and ipatropium bromide plus nebulized fenoterol (Berodual®) in asthma patients with ages ranging between 5 and 12 years who suffer acute asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics. Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders? Year: 2010
A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002
Efficacy and safety of a novel nicotine mouth spray in smoking cessation: A randomized, placebo-controlled, double blind, multicenter study with 52-week follow up Source: Annual Congress 2011 - Smoking cessation science Year: 2011
A multicentre, double-blind, double-dummy, randomized, parallel group study to assess efficacy and safety of beclomethasone dipropionate and ease of handling of a breath operated aerosol inhaler in adults with reversible airways obstruction Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Open, randomized, two-way crossover, pilot study to assess the effect of salbutamol in comparison with ipratropium bromide on central and peripheral airway dimensions in COPD patients Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients Year: 2009
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018